Networks and Collaborations

Showing results filtered by:

The Accelerating Medicines Partnership (AMP) brings high-level government, industry, and non-profit foundation partners together to identify and validate the most promising biological targets for therapeutics. The partners have designed a bold milestone-driven research plan to tackle the challenge for the autoimmune diseases of rheumatoid arthritis and systemic lupus erythematosus (lupus). One of the features that makes this public-private partnership unique is that AMP data will be publicly accessible to the broad biomedical community for further research.

Adjuvant Development Program

NIAID initiated this program in 2008 to advance novel vaccine adjuvants toward licensure for human use. The program, which was renewed in 2013, supports the optimization of adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.

The mission of the ACTG Network is to reduce the burden of disease due to HIV, tuberculosis, and viral hepatitis.

NIAID launched the ARLG in 2013, a major new clinical effort to address antibacterial resistance (AR). Studies conducted by the ARLG may include clinical testing of new drugs to treat multidrug-resistant Gram-negative bacteria, evaluating diagnostic devices in clinical settings, evaluating the effectiveness of new antibacterial stewardship programs, and optimizing treatment regimens to reduce the emergence of resistance. The ARLG is drawing on the creativity of the global research community by inviting concept submissions to identify and address AR priorities.

The AADCRCs are the cornerstone of NIAID efforts to promote multidisciplinary basic and clinical research focusing on the immunological basis, pathobiology, diagnosis, treatment, and prevention of asthma and allergic diseases. The original program, established in 1971, was the first targeted program to promote research in the field of asthma and allergic diseases. Over the years, the centers have conducted groundbreaking research on key aspects of asthma and allergic diseases. These include the central role of immunoglobulin E antibodies in allergy and asthma, the role of eosinophils and mast cells (both types of immune cells that can release histamine) in allergic inflammation, the role of leukotrienes (signaling molecules that trigger contractions in the smooth muscles lining the windpipe), and the importance of indoor allergens and ambient air pollution in asthma.

The ACEs conduct collaborative basic and clinical research on autoimmune diseases. Close interaction between clinicians and basic researchers accelerates the discovery, development, and translation of therapies for autoimmune diseases from the lab to use in the clinic. 

CHAVI, which was established by NIAID as part of the Global HIV/AIDS Vaccine Enterprise, is designed to answer basic science questions relevant to HIV vaccines and to conduct early phase HIV vaccine clinical trials at clinical sites around the world.

CIDI is a partnership between NIAID and Radiology and Imaging Sciences at the National Institutes of Health Clinical Center. It was established in 2009 to perform basic science, translational, and clinical research on the imaging features of infectious disease, including CT, nuclear medicine, MRI, ultrasound, radiography, and optical modalities. CIDI continues to provide subject matter expertise, technical support, education, and outreach while bringing together state-of-the-art imaging science with infectious disease research to enhance our understanding of the pathophysiology and treatment of immunologic and infectious diseases. CIDI has partnered with the NIAID Integrated Research Facility at Fort Detrick, Maryland, to offer opportunities for investigators to apply advanced imaging technologies to infectious disease research.

The CIBMTR database contains data on outcomes of hematopoietic (blood and bone marrow) cell transplant (HCT) procedures. Currently, the database includes information on more than 325,000 HCT recipients from 500 U.S. transplant centers. The CIBMTR collaborates with government agencies, professional groups, international partners, and patient organizations via 15 active scientific/research working committees. This collaboration ensures that high-quality data are available to an international community of investigators, physicians, and patients to advance understanding and improve success of HCT for the treatment of autoimmune and other diseases. The CIBMTR database is co-funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute.

The CFAR program at the National Institutes of Health provides administrative and shared research support to synergistically enhance and coordinate high quality AIDS research projects. CFARs accomplish this through core facilities that provide expertise, resources, and services not otherwise readily obtained through more traditional funding mechanisms.

The CEIRS program continues and expands the Institute's animal influenza surveillance program internationally and domestically and focuses on several high priority areas in influenza research. The overall goal of this program is to provide the government with public health tools and strategies needed to control and lessen the impact of epidemic influenza and the increasing threat of pandemic influenza.

CETR seeks to advance discovery, preclinical development, production, licensure and/or use of new or improved medical countermeasures (therapeutics, immunotherapeutics, vaccines, vaccine technologies, and medical diagnostics) or related technologies for emerging and re-emerging infectious diseases. 

The purpose of this consortium is to study the manufacture and transplantation of pancreatic islets, the insulin-producing cells of the pancreas, for the treatment of type 1 diabetes, an autoimmune disease. CITC is a network of clinical centers in the United States, Canada, and Nordic countries that are conducting clinical trials in pancreatic islet transplantation. This program is co-sponsored with NIDDK and is funded by the Special Statutory Funding Program for Type 1 Diabetes Research.

The CTOT program is an investigative consortium that conducts clinical and associated mechanistic studies to improve outcomes for transplant recipients.

The CTOT-C program focuses on the specific challenges associated with pediatric organ transplantation. The purpose of these studies is to improve short- and long-term graft and patient survival in children who have undergone heart, lung, or kidney transplantation. This program is a continuation of first NIAID pediatric transplantation clinical trial consortium, the Cooperative Clinical Trials in Pediatric Transplantation program.

Community Partners (CP) is a group established to promote effective representation of and timely communication among the many communities, in the United States and internationally, that work with and participate in the National Institutes of Health (NIH)-funded HIV/AIDS Clinical Trials Networks.

CoFAR was established in fiscal year (FY) 2005 to support clinical research on food allergy. It was renewed in FY 2010 to continue several promising clinical studies from the original consortium and expanded to include research on the genetic causes underlying food allergy and the mechanisms of food allergy-associated eosinophilic esophagitis (EoE).

CONRAD is focused on facilitating the rapid development of safe, acceptable, affordable products and methods that provide contraception and/or prevent the sexual transmission of HIV/AIDS and other infections.

Cooperative Centers for Translational Research on Human Immunology and Biodefense

The mission of these research centers is to further our knowledge of human immune responses against infectious pathogens and to understand the molecular mechanisms responsible for both short-term immunity and long-term immune memory. The program aims to translate research on immunity into clinical applications to protect people from potential agents of bioterrorism.

CSGADP was established in 2001 as a collaborative network of investigators with a focus on halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression, with an emphasis on Type 1 diabetes.